Radiologic findings following Y90 radioembolization for primary liver malignancies.
A therapy gaining rapid clinical adoption involves radioembolization with the use of Yttrium-90 (90Y) microspheres. The 20-60 microm-sized microspheres are injected trans-arterially and flow to hepatic tumors given their preferential blood supply from the hepatic artery. Once they lodge in the arterioles, they impart a very intense local radiotherapeutic effect. Given the combined radiation and embolic effect, the imaging findings imparted by this mode of action differ significantly from other treatments. This work represents a comprehensive review of the imaging findings following radioembolization in patients with primary liver tumors. The report discusses imaging response, benign secondary effects, and complications. This should help educate the radiologist on imaging findings that should be expected following radioembolization and therefore aid in the proper image interpretation.
Ibrahim
Saad M
SM
Department of Radiology, Northwestern Memorial Hospital, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA.
Nikolaidis
Paul
P
Miller
Frank H
FH
Lewandowski
Robert J
RJ
Ryu
Robert K
RK
Sato
Kent T
KT
Senthilnathan
Sean
S
Riaz
Ahsun
A
Kulik
Laura
L
Mulcahy
Mary F
MF
Omary
Reed A
RA
Salem
Riad
R
D014408:Biomarkers, Tumor / Q000032:analysis; D003287:Contrast Media; D003937:Diagnosis, Differential; D004621:Embolization, Therapeutic / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D007269:Injections, Intra-Arterial; D008113:Liver Neoplasms / Q000098:blood supply / Q000175:diagnosis* / Q000532:radiotherapy*; D008279:Magnetic Resonance Imaging; D008863:Microspheres; D018579:Patient Selection; D014055:Tomography, Emission-Computed; D014057:Tomography, X-Ray Computed; D015021:Yttrium Radioisotopes / Q000627:therapeutic use*
D014408:Biomarkers, Tumor; D003287:Contrast Media; D015021:Yttrium Radioisotopes